FORA Capital’s Karyopharm Therapeutics KPTI Stock Holding History

FORA Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-250	Closed	-$72K	–	1122
2020 Q1	$72K	Buy	+250	New	+$69K	0.02%	690

Other funds holding KPTI

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FORA Capital's KPTI Position: Q2 2020 in Review

FORA Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 250 shares — an estimated $72K sold.

FORA Capital first reported a position in KPTI in Q1 2020 and held it in 1 quarter. The position peaked at $72K in Q1 2020. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

FORA Capital reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
FORA Capital sold 250 Karyopharm Therapeutics shares in Q2 2020, an estimated $72K.
FORA Capital first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 1 quarter.
FORA Capital's Karyopharm Therapeutics position peaked at $72K in Q1 2020.
155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on FORA Capital's 13F filing for Q2 2020, filed 14 Aug 2020.